Drugs / EYP001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03469583 | Feb → Jun 2018 | chronic hepatitis B virus infection | Enyo Pharma | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-11-19 | Enyo Pharma | Vonafexor accepted as the generic name for EYP001 by the WHO enyopharma.com ↗ |
| 2017-12-13 | Enyo Pharma | Collaboration with Imperial College to evaluate EYP001 enyopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYP001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469583 ↗ |
| Route | Oral | “EYP001 capsules by mouth” NCT03469583 ↗ |